KEY POINTS:
Genesis Research and Development Corporation said yesterday it had entered a research partnership with an international developer in therapeutic human antibodies.
Its partnership with German-listed MorphoSys AG would allow Genesis to continue to use certain antibodies originally generated by MorphoSys' business unit, AbD Serotec.
Genesis is
